SNGX News Alert Soligenix Inc. (SNGX) 1.9300 10/01/2014 21:0

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Soligenix Inc. (SNGX) 1.9300 $SNGX

Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Revises Price Target Higher From $5.50 to $7.00
Marketwire - Wed Sep 24, 8:01AM CDT
Vista Partners announced today that it has updated coverage on Soligenix, Inc. (OTCBB: SNGX), based in Princeton, New Jersey, and revised its twelve-month price target higher from $5.50 to $7.00. Ross Silver, Principal Analyst at Vista Partners, stated, "The Company boasts a diverse pipeline with ten prospective drug candidates, including a Phase 3 ready asset slated to enter the clinic in early 2015. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. The Company has been awarded numerous government grants and entered into strategic agreements with two companies, Intrexon (~$1.9B mkt cap.) and SciClone (~$360M mkt cap). The main financial contributor has been the U.S. government. To date, the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. On top of the $7.1M financing completed in 2013, the Company has up to approximately $57 million in active government contracts and grant funding still available to support its associated research programs through 2018. The Company is in the process of petitioning and filling applications for a number of additional grants for further support of its programs with various funding agencies."

Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
PR Newswire - Tue Sep 23, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has appointed Rasappa Arumugham, PhD, as its Vice President of Biopharmaceutical Development. Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development (R&D) in the areas of formulation research, analytical method development, quality control (QC), and manufacturing. He has a proven track record in development, scale-up, and technology transfer supporting commercialization of vaccines and biologics, including Prevnar®, TetramuneTM, HibTITER®, Meningitec® Conjugate and meningitis B (bivalent rLP2086) Lipoprotein Subunit Vaccines.

Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax(TM) Vaccine
PR Newswire - Fri Sep 19, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID). The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax(TM), combined with the company's ricin toxin vaccine, Rivax(TM), as a medical countermeasure (MCM) to prevent the effects of ricin exposure.

Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma
PR Newswire - Wed Sep 17, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that agreement has been reached with the US Food and Drug Administration (FDA) on the design of a pivotal, Phase 3 clinical trial evaluating its product SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL).

Soligenix Announces Issuance of US Patent for ThermoVax(TM) Technology
PR Newswire - Tue Sep 09, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the US Patent and Trademark Office (US PTO) granted patent 8,808,710 entitled "Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition." The newly issued patent claims cover compositions and methods for manufacturing vaccines utilizing ThermoVax(TM), the Company's proprietary vaccine thermostabilization technology.

Soligenix to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
PR Newswire - Mon Sep 08, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City, Tuesday, September 9, at 1:15 PM Eastern Daylight Time. The presentation will take place in the Kennedy I Salon at the New York Palace Hotel.

Soligenix Expands Pipeline with Acquisition of Phase 3-Ready Oncology Clinical Program
PR Newswire - Fri Sep 05, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin). SGX301 is poised to enter pivotal Phase 3 clinical testing for the treatment of cutaneous T-cell lymphoma (CTCL) and is highly synergistic with the company's existing development pipeline. As part of the acquisition, Soligenix acquired all rights for synthetic hypericin, including intellectual property, and preclinical and clinical data.

Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine
PR Newswire - Tue Sep 02, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax(TM), in a non-human primate (NHP) lethal aerosol exposure model. The study demonstrated that NHPs vaccinated with RiVax(TM) were completely protected against a lethal aerosol of ricin toxin with a highly significant survival benefit (p<0.002). RiVax(TM), manufactured with the Company's thermostabilization platform technology ThermoVax(TM), was used to vaccinate NHPs to assess efficacy against lung exposure to ricin toxin in an animal model that is anticipated to respond to vaccination similarly to humans. ThermoVax(TM) provides for stabilized, lyophilized (freeze-dried) subunit vaccines that are resistant to exposure to heat, avoiding refrigeration during storage and distribution.

Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments
PR Newswire - Mon Aug 11, 6:30AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the second quarter and six months ended June 30, 2014.

Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax(TM)
PR Newswire - Thu Aug 07, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax(TM). Previous studies had demonstrated that VeloThrax(TM) also possesses enhanced thermostability, enabling distribution without cold chain requirements.

Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield(TM) in GI ARS
PR Newswire - Fri Aug 01, 6:30AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShieldTM (oral beclomethasone 17,21-dipropionate or oral BDP). The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield(TM) as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS). NIAID granted an initial award of $2.1 million to Soligenix on September 18, 2013. The total contract award is valued at up to $6.4 million over three years.

Soligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection
PR Newswire - Wed Jul 09, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the combination of RiVax(TM) and VeloThrax(TM) induces protective immunity to both ricin toxin and anthrax toxin exposure. RiVax(TM) is the Company's candidate vaccine for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. VeloThrax(TM) is the Company's candidate vaccine that employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine.

Soligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments
PR Newswire - Wed Mar 26, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013.

Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target
Marketwire - Tue Mar 18, 8:02AM CDT
Vista Partners announced today that it has initiated coverage on Soligenix, Inc. (OTCBB: SNGX) with a twelve-month price target of $5.50. Soligenix, Inc. is a New Jersey based clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases. Ross Silver, Principal Analyst at Vista Partners, stated, "Soligenix has signed an exclusive worldwide collaboration deal with Intrexon Corporation ($2.9B mkt cap) (NYSE: XON) to develop a novel passive immunotherapy for Melioidosis. Melioidosis, also known as Bp, is an often deadly infectious disease caused by the bacterium, Burkholderia pseudomallei, with some symptoms similar to those of the flu and pneumonia. Melioidosis occurs in many different places around the globe, currently however it is of greatest concern in southeast-Asia and northern Australia, where public officials see it as a major threat to the health of the population." Mr. Silver continues, "The Company also has an exclusive commercial collaboration with SciClone Pharmaceuticals ($250M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment of oral mucositis." Mr. Silver concludes, "The Company boasts a diverse pipeline with nine prospective drug candidates. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. To date the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. The Company has up to approximately $34 million in active government contract and grant funding still available to support its associated research programs through 2018."

Soligenix to Present at 2014 World Vaccine Congress in Washington, DC
PR Newswire - Tue Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the 2014 World Vaccine Congress - Biotech Showcase on Tuesday, March 25, 2014. The presentation will take place at 2:10 PM Eastern Daylight Time (EDT) at the Marriott Wardman Park Hotel in Washington, DC, where Dr. Brey will, in part, review the Company's achievements to date with its ThermoVax(TM) vaccine heat stabilization technology.

Soligenix Inc receives USD300,000 NIAID SBIR grant to support further evaluation of SGX943 for the treatment of melioidosis
M2 - Mon Feb 17, 6:00AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Friday the receipt of USD300,000 Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 for the treatment for melioidosis.

Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.

Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Wed Feb 05, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16th Annual BIO CEO Investor Conference in New York City, on Monday, February 10, 2014 at 3:00 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.

B&B Music Lessons in the Mid-Atlantic Celebrates Ninth Anniversary
PR Newswire - Tue Feb 04, 7:30AM CST
B&B Music Lessons, based in Washington, D.C., is celebrating its ninth anniversary this March. Owners Brad Clements and Bhagwan Khalsa are pleased with the progress they've made since starting the business in 2005. The school currently has 65 teachers and 370 students, mostly age five to 15.

U.S. Chamber's Global IP Center Unveils 2014 International Intellectual Property Index
PR Newswire - Tue Jan 28, 11:01PM CST
Report Sheds Light on Progress, Deficiencies in 25 Countries' IP Environments, Including Select TPP Participants




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 55

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 0

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

Colossus SSP Partners with Scope3 for Sustainable Advertising

Updated Category News Views 852

Colossus SSP Teams Up with Scope3 for Green Media Solutions Colossus Media LLC, also known as Colossus SSP, is making strides in the advertising sector by integrating with Scope3, a prominent provider of carbon emissions data. This collaboration empowers Colossus SSP to present superior green media solutions, thereby allowing brands and agencies to show greater commitment...

Continue Reading
SSC Security Services Enhances Structure Through Amalgamation

Updated Category News Views 110

SSC Security Services Corp. Completes Subsidiary Amalgamation SSC Security Services Corp., commonly referred to as SSC, is pleased to announce the successful completion of a horizontal short-form amalgamation of its wholly owned operating subsidiaries, Logixx Security Inc. and SRG Security Resource Group Inc. This strategic move is part of a larger effort to streamline...

Continue Reading
Biden Administration Takes Action to Enhance Airline Competition

Updated Category News Views 64

Biden Administration Takes a Firm Stand on Airline Competition The U.S. government is stepping up efforts to ensure fair competition in the airline industry. The Justice Department's Antitrust Division, along with the Transportation Department, has initiated a comprehensive public inquiry into the landscape of air travel competition. Prioritizing Airline Competition...

Continue Reading
Atlassian Reports Exceptional Growth in Fiscal Performance

Updated Category News Views 101

Atlassian's Strong Fiscal Performance Atlassian Corp Plc (NASDAQ: TEAM) has recently delivered its fiscal first quarter results, much to the delight of analysts and investors alike. The report highlighted impressive growth in both its cloud and data center sectors, which significantly contributed to its revenues, surpassing Wall Street's expectations. Highlights from the...

Continue Reading
Actinium Pharmaceuticals Lawsuit: What Investors Should Know Now

Updated Category News Views 238

Actinium Pharmaceuticals Class Action Lawsuit Overview In recent developments surrounding Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), investors are presented with an opportunity to lead a securities fraud class action lawsuit. This initiative is spearheaded by Rosen Law Firm, a reputable global entity vigorously advocating for investor rights. Key Details for...

Continue Reading